How Multi-Omics Integration Is Revealing New NSCLC Subtypes

Non-small cell lung cancer (NSCLC) is often described through familiar categories such as adenocarcinoma, squamous cell carcinoma and large-cell carcinoma. These labels remain clinically useful, yet they can conceal important biological differences. Two tumours that look alike under a microscope may carry different mutations, activate different immune pathways and respond very differently to the same treatment.

Multi-omics integration brings several layers of molecular information together to create a more detailed picture of each cancer. Genomics, transcriptomics, epigenomics, proteomics, metabolomics, single-cell analysis and spatial biology can reveal previously unrecognised NSCLC subgroups. For Australian researchers and health services, this approach offers a route towards more precise diagnosis, treatment selection and follow-up care.

Why Tissue Looks Different

A lung tumour is rarely a single, uniform mass. It contains cancer cells with different genetic changes, immune cells, blood vessels, connective tissue and regions affected by low oxygen. This internal diversity is called tumour heterogeneity, and it helps explain why a treatment may shrink one part of a tumour while another area continues growing.

Traditional pathology provides essential information about cell appearance and tissue structure. Molecular profiling adds another layer by identifying changes such as EGFR, ALK, ROS1, KRAS, BRAF, MET and RET alterations. It can also show whether tumour cells have developed resistance after exposure to a targeted therapy.

The challenge is that a single biopsy may not capture the full disease. A sample from one lung lesion can differ from tissue in a lymph node or a distant metastasis. Multi-omics studies address this limitation by comparing multiple samples, blood-based signals and data collected over time.

What Multi-Omics Adds

Each “omics” technology answers a different question. DNA sequencing identifies inherited or acquired variants, while RNA analysis shows which genes are active. Epigenomic testing examines chemical marks that regulate gene expression. Proteomics measures proteins driving cell behaviour, and metabolomics tracks the chemical products of cellular activity.

Combining these data types can expose relationships that one test would miss. A DNA alteration may be present, for example, but its effect may depend on RNA activity, protein production or an immune-suppressing environment. Single-cell sequencing can separate signals from cancer cells and neighbouring immune cells, while spatial transcriptomics shows where those signals are located within the tumour.

This integrated view is similar to assembling a complex clinical picture from pathology, imaging and patient history. Research translation is essential if these discoveries are to move beyond specialist laboratories, as shown by the Queensland antibiotic journey.

Hidden Lung Cancer Subtypes

Recent studies have identified molecular patterns that cut across conventional NSCLC categories. Some tumours show strong immune activation and may be more likely to respond to immune checkpoint inhibitors. Others contain an immune-excluded environment, where immune cells are present around the tumour but cannot effectively enter it.

Researchers are also finding subgroups linked to specific mechanisms of treatment resistance. A tumour may initially depend on an EGFR signal, then activate alternative pathways after therapy. Another may undergo a change known as epithelial-to-mesenchymal transition, becoming more mobile, invasive and less sensitive to existing drugs.

Metabolic subtypes are attracting attention as well. Certain cancers rely heavily on glucose, fatty acids or altered amino acid pathways. These differences could help researchers identify new drug targets or combine standard treatment with therapies that disrupt tumour metabolism. The goal is not to create labels for their own sake, but to connect biological subtypes with decisions that improve outcomes.

From Molecular Signals to Treatment

A more detailed tumour classification could help oncologists select targeted therapies, immunotherapy, chemotherapy or combinations with greater confidence. It may also identify patients who need closer monitoring because their cancer has a high likelihood of early progression or treatment resistance.

Multi-omics data may support the development of predictive biomarkers. These biomarkers could indicate whether a patient is likely to benefit from a particular medicine, rather than simply describing what the tumour looks like. In time, repeated blood tests might help detect molecular changes before they become visible on scans.

Implementation must remain clinically practical. A test that takes too long, requires scarce tissue or produces results that clinicians cannot interpret will have limited value. Researchers therefore need to compare the accuracy, cost, turnaround time and patient benefit of different testing strategies.

Australian Research and Care Settings

Australia has a strong foundation for this work through partnerships among universities, medical research institutes, pathology services and hospitals. In Brisbane, collaboration across major health services can connect laboratory discoveries with clinical trials and routine care. The Brisbane Diamantina network illustrates how research translation can bring multiple disciplines and patient-focused priorities together.

Local conditions shape how precision oncology is delivered. Patients may travel from regional Queensland to Brisbane for specialist testing, making timely reporting and telehealth coordination important. Health services also need approaches that work for rural communities and Aboriginal and Torres Strait Islander peoples, with culturally safe consent processes and meaningful community engagement.

Data governance is equally important. Australian researchers must work within privacy requirements, including the Privacy Act 1988, as well as human research ethics frameworks and institutional governance. Testing pathways may also involve National Association of Testing Authorities accreditation, Therapeutic Goods Administration requirements and funding considerations linked to Medicare or the Pharmaceutical Benefits Scheme.

Barriers to Trustworthy Classification

The biggest scientific obstacle is data complexity. Multi-omics datasets can contain millions of measurements, and a statistical association does not automatically prove that a biological pathway causes treatment response. Studies need well-characterised patient groups, appropriate controls and independent validation in different hospitals and populations.

Cost and access are practical concerns. Advanced sequencing and spatial analysis remain expensive, while smaller health services may lack specialist bioinformaticians. Australian research programs must also consider whether a proposed test can be sustained within public hospitals rather than relying entirely on grant funding.

Patient consent requires careful explanation. Genomic information may reveal inherited cancer risk, raise questions for relatives and create concerns about insurance or privacy. Clear communication, secure data handling and transparent rules about data sharing are central to maintaining trust.

What Clinical Implementation Could Look Like

A future NSCLC pathway may begin with standard pathology and a broad molecular panel, followed by more specialised testing when the first results are inconclusive or the disease changes. Multi-omics analysis could then combine tumour tissue, blood samples, imaging and treatment history into a clinically interpreted report.

Clinical teams will need integrated reports that distinguish established findings from exploratory signals. Molecular tumour boards, supported by pathologists, oncologists, genetic counsellors, data scientists and patients, can help translate complex results into responsible decisions.

The same partnership model can support other health priorities. Work examining gestational diabetes in young mothers demonstrates how research, prevention and health-service practice can be connected around the needs of Queensland communities.

Researchers, clinicians and health leaders can help shape this next phase by supporting well-designed studies, responsible data governance and equitable access to molecular testing. Following Brisbane Diamantina Health Partners’ research and collaboration opportunities is one practical way to stay connected with advances that aim to make lung cancer care more precise, timely and useful for Australian patients and families.